OTCMKTS:CLPBY Coloplast A/S Q3 2025 Earnings Results & Report $7.04 +0.16 (+2.33%) As of 03:57 PM Eastern Coloplast A/S missed analyst expectations on both earnings and revenue in its Q3 2025 results, released August 19, 2025. The company reported EPS of $0.06 versus the $0.0920 consensus estimate, while revenue of $1.09 billion fell short of the $7.10 billion estimate by $6.01 billion. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateAugust 19, 2025TimeBefore Market Opens Coloplast A/S EPS ResultsActual EPS$0.06Consensus EPS $0.0920Beat/MissMissed by -$0.0320One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersColoplast A/S Revenue ResultsActual Revenue$1.09 billionExpected Revenue$7.10 billionBeat/MissMissed by -$6.01 billionYoY Revenue GrowthN/AUpcoming EarningsColoplast A/S' next earnings date is estimated for Tuesday, November 3, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Coloplast A/S Q3 2025 Earnings FAQ Did Coloplast A/S beat earnings estimates for Q3 2025? Coloplast A/S (OTCMKTS:CLPBY) reported earnings of $0.06 per share for Q3 2025, missing the consensus estimate of $0.0920. The report was announced on Tuesday, August 19, 2025. What was Coloplast A/S' revenue for Q3 2025? Coloplast A/S reported revenue of $1.09 billion for Q3 2025, against a consensus estimate of $7.10 billion. When is Coloplast A/S' next earnings date? Coloplast A/S' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Coloplast A/S on the company's earnings history page. Coloplast A/S Earnings HeadlinesColoplast A/S (OTCMKTS:CLPBY) Stock Price Up 3.9% - Should You Buy?October 12 at 11:41 AM | americanbankingnews.comHead to Head Analysis: Elutia (NASDAQ:ELUT) and Coloplast A/S (OTCMKTS:CLPBY)October 5, 2026 | americanbankingnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 15 at 1:00 AM | Base Camp Trading (Ad)CLPBY Share News TodayJune 22, 2026 | uk.investing.comColoplast's Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of menJune 3, 2026 | globenewswire.comColoplast: Went 'BUY' A Bit EarlyMay 16, 2026 | seekingalpha.comSee More Coloplast A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Coloplast A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coloplast A/S and other key companies, straight to your email. Email Address About Coloplast A/SColoplast A/S (OTCMKTS:CLPBY) is a Denmark-based medical technology company that develops and markets products and services for people with intimate and chronic healthcare needs. Its principal business areas include ostomy care, continence care, wound and skin care, and interventional urology. The company’s product portfolio includes ostomy bags and accessories, skin-protection products, intermittent catheters, bowel-management systems, and devices used in urological procedures. Recognized brands include SenSura and Brava in ostomy care, SpeediCath in continence care, and Peristeen for bowel management. Coloplast traces its origins to the 1950s, when nurse Elise Sørensen developed an adhesive ostomy bag to help her sister manage an ileostomy. The company was established in 1957 by Aage Louis-Hansen and his wife, Johanne Louis-Hansen. Headquartered in Humlebæk, Denmark, Coloplast serves healthcare professionals and patients in markets across Europe, North America, and other international regions. Kristian Villumsen has served as the company’s president and chief executive officer.View Coloplast A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
